34 results
8-K
EX-99.1
IOBT
IO Biotech Inc
14 May 24
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
8:30am
for the three months ended March 31, 2024, was $19.5 million, compared to $17.0 million for the three months ended March 31, 2023.
Research and development … the continued execution of the company’s pivotal Phase 3 clinical trial. The company recognized $0.6 million in research and development equity-based
8-K
EX-99.1
IOBT
IO Biotech Inc
5 Mar 24
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
4:46pm
.
Research and development expenses were $21.8 million for the three months ended December 31, 2023, compared to $14.4 million for the three months ended … candidate, including the continued execution of the company’s Phase 3 clinical trial. The company recognized $0.5 million in research and development
8-K
cc6xvmfsoovs aoq88pw
13 Nov 23
IO Biotech Announces 2023 Third Quarter Results
8:10am
8-K
EX-99.2
2no 5e94pekz
13 Nov 23
IO Biotech Announces 2023 Third Quarter Results
8:10am
8-K
EX-99.1
csnghcfl
13 Nov 23
IO Biotech Announces 2023 Third Quarter Results
8:10am
424B2
0171416k60 ts
12 Sep 23
Prospectus for primary offering
4:06pm
8-K
EX-99.1
efcdelk ynv4n
11 Aug 23
IO Biotech Announces 2023 Second Quarter Results
8:31am
8-K
EX-99.2
57q0nqqifms sao9gb
7 Aug 23
IO Biotech, Inc. Announces $75 Million Private Placement Financing
8:31am
8-K
EX-99.1
vmma7f7
11 May 23
IO Biotech Announces 2023 First-Quarter Results
4:05pm
8-K
EX-99.1
q6y4a3kq7ppb atws
9 Nov 22
IO Biotech Announces Third Quarter Results for 2022
4:06pm
8-K
EX-99.1
7ng9i
11 Aug 22
IO Biotech Announces Second Quarter Results for 2022
4:38pm
8-K
EX-99.1
k7g m52vymiv
16 May 22
IO Biotech Announces First Quarter Results for 2022
12:00am